Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval
Drug Addresses 1%-2% Of NSCLC Patients
Nov 16 2023
•
By
Mandy Jackson
ROS1-positive NSCLC patients tend to be younger and women • Source: Shutterstock
More from New Products
More from Scrip